Pascal Soriot (Sipa via AP Images)

A tale of two vac­cines: As­traZeneca's shot still a block­buster, but Pfiz­er sales are on an­oth­er lev­el

With As­traZeneca’s sec­ond quar­ter earn­ings call Thurs­day morn­ing came up­dat­ed sales num­bers for its Covid-19 vac­cine — and com­pared to the big mR­NA play­ers, the num­bers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.